ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Genentech and Inotek Pharmaceuticals will jointly develop and commercialize inhibitors of poly(ADP-ribose) polymerase (PARP), a nuclear enzyme involved in the repair of damaged DNA, for the treatment of cancer. Inotek will receive a $20 million up-front payment and could reap an additional $405 million in milestone payments. Genentech will pay Inotek royalties on its lead PARP inhibitor, INO-1001, currently in Phase Ib testing for skin cancer. As part of the deal, Genentech also has the option to develop Inotek's PARP inhibitors for cardiovascular indications. If exercised, the option could be worth another $200 million to Inotek.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X